Earlier response assessment in invasive aspergillosis based on the kinetics of serum aspergillus galactomannan: Proposal for a new definition

Clinical Infectious Diseases

Volumn 53, Issue 7, 2011, Pages 671-676

  Nouér, Simone A ^a,b   Nucci, Marcio ^a,b   Kumar, Naveen Sanath ^b   Grazziutti, Monica ^b   Barlogie, Bart ^b   Anaissie, Elias ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN;

ADULT; AGED; ARTICLE; ASPERGILLUS; AUTOPSY; CORRELATION COEFFICIENT; EUROPE; FEMALE; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SERUM;

ADULT; AGED; AGED, 80 AND OVER; DRUG MONITORING; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MANNANS; MIDDLE AGED; SERUM; TIME FACTORS;

EID: 80052426714     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir441     Document Type: Article

References (31)

1. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112:2309-12. (Pubitemid 351628643)
2. Anaissie EJ. Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44: 1298-306. (Pubitemid 46717291)
3. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47:674-83.
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15. (Pubitemid 34851833)
5. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97. (Pubitemid 46717290)
6. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-43. (Pubitemid 36724481)
7. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115:355-62.
8. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412-22. (Pubitemid 351589942)
9. Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:830-4. (Pubitemid 47257661)
10. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44:1329-36. (Pubitemid 46729195)
11. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23. (Pubitemid 34031596)
12. Nucci M, Nouer SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010; 51:1273-80.
13. Chmura KH, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med 2002; 21:2109-29. (Pubitemid 34752626)
14. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57:732-40.
15. Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56:594-7. (Pubitemid 41264143)
16. Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53:131-9. (Pubitemid 44028669)
17. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34:939-43. (Pubitemid 34229762)
18. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255-60.
19. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8. (Pubitemid 29455209)
20. Pagano L, Ricci P, Nosari A, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission: a retrospective study and review of the literature. Br J Haematol 1995; 89:500-5.
21. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110:112-20. (Pubitemid 46986424)
22. Kawel N, Schorer GM, Desbiolles L, Seifert B, Marincek B, Boehm T. Discrimination between invasive pulmonary aspergillosis and pulmonary lymphoma using CT. Eur J Radiol 2011; 77:417-25.
23. Parrón M, Torres I, Pardo M, Morales C, Navarro M, Mart́nez-Schmizcraft M. The halo sign in computed tomography images: differential diagnosis and correlation with pathology findings [in Spanish]. Arch Bronconeumol 2008; 44:386-92.
24. Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8:128-39. (Pubitemid 44201948)
25. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-9. (Pubitemid 38982107)
26. Vallor AC, Kirkpatrick WR, Najvar LK, et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother 2008; 52:2593-8. (Pubitemid 351915692)
27. Becker MJ, de Marie S, Willemse D, Verbrugh HA, Bakker-Woudenberg IA. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000; 38: 1434-8. (Pubitemid 30217861)
28. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-69. (Pubitemid 32182037)
29. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97:1604-10. (Pubitemid 32217224)
30. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91:986-9. (Pubitemid 44023159)
31. Ellenberg SS. Biostatistics in clinical trials: part 2-determining sample sizes for clinical trials. Oncology (Williston Park) 1989; 3: 39-46.